BioLargo provides innovative solutions for clean water, clean air, and advanced wound care through patented technologies and engineering services. It has 20 patents and 5 pending patents across four operating units. Recent headlines include achieving profitability for the first time, winning USAF contracts, and demonstrating an effective PFAS treatment technology. CupriDyne Clean is commercialized for odor control and expanding into new markets like cannabis. The AOS water treatment technology shows potential as a low-cost solution for removing micropollutants.

1. Innovator & Sustainable
Solutions Provider
Technologies and Engineering for Clean Water,
Clean Air, and Advanced Wound Care
Safe Harbor Statement
The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the
forward-looking statements, including, but not limited to, the risks and uncertainties included in BioLargo's current and future filings with the Securities and Exchange Commission, including those set forth in BioLargo's
Annual Report on Form 10-K. This presentation includes estimates of market size, revenue per client site and revenue based upon customer adoption rates. All such statements are forward-looking statements and,
although based upon assumptions the Company believes to be reasonable, are not projections of actual revenue or earnings which may be substantially less. There can be no guaranty that any national account
customer adopts the use of our products and we cannot predict the adoption rate, if any, by our customers and potential customers. Revenue per customer site may be affected by many factors, including but not
limited due to distribution, price competition, fluctuating supplier pricing, size, population density, location and weather.
Stock Symbol: BLGO Westminster, CA

2. Innovative solutions –
Patented products, technologies, and talent
• 20 Patents & 5
Pending
• Proven platform
technologies
• Veteran
environmental
engineering team
with global industry
leadership
experience
Commercial
Nearing Commercial Launch
Supported w/ Direct 3rd Party
Investment + 69 Grants
2

3. Nature Shows Us the Way!
3
Inspiration from
one discovery …
…leads to an
ever-expanding IP
portfolio across
four operating
units

4. 4
Recent Headlines
 Cleantech Company of the Year- SustainSoCal.org
 Breaking revenue records
 Retired variable priced debt (≅ $300k left) & cleaning up
balance sheet
 Solution to PFAS national crisis – BioLargo
Engineering's AEC is affordable, effective solution
 FDA 510 (k) clearance first wound care product

5. 5
 Odor-No-More turned positive cash flow and now growing with
nominal capital from BLGO + cash from operations
 Leveraging manufacturing through expanding distribution channels
for CupriDyne Clean
• Asia + Cannabis & Hemp Markets
 BioLargo Engineering achieves record revenue and turns first
profitable month as it wins USAF contracts and 8 more bids in
process with potential for 25 more contracts
 First BioLargo Water customer requests a complete clean water
solution after successful demonstration pilot – poultry process water
 Stormwater demonstration pilot grant awarded and started
Recent Headlines

6. 6
CupriDyne Clean proven effective in third party study to
control Hydrogen Sulfide (H2S) – Expanding existing
product use
• Waste Management Industry
• Wastewater Treatment
• Well Water
• Oil & Gas
• Shipping Industry
• Paper Industry
• Glue Industry
Recent Headlines

7. 7
Financial Highlights from Quarterly Report
• Revenue grew 93%
compared with third quarter
2018- $534,000 for quarter
• Revenue grew 53%
compared with nine-months
2018 - $1,324,000 for YTD
• Quarter over quarter
revenues averaging a 25%
increase for the past 3 years
-
50,000
100,000
150,000
200,000
250,000
300,000
350,000
400,000
450,000
Axis Title
Odor No More Revenue by Quarter 2017-2019

8. 8
Highlights from Quarterly Report
Odor-No-More
• Full-Service Odor and VOC Solution Serving Top 4
Customers in Waste Handling Industry
• Breaking Sales Records
 Expected to GROW Region by Region
• Signed a MOU with #1 WWT company in S. Korea to
serve Asia
• Secured first customers in the cannabis and hemp
industry through distributor & sales are ramping up -
proven effective

9. 9
• Revenues grew 385% in the nine months
ended September 30, 2019 (over last year)
• Revenues grew 284% in the three months
ended September 30, 2019 (compared to Q3
2018)
• In Q3-showed an operating profit for the first
time since its inception two years ago
• Developed PFAS Solution with EPA grant
• Won USAF contracts to serve 7 bases secured
and bids to 20+ more in the works
• and More!
BioLargo Engineering Recent Highlights from
Quarterly Report

10. 10
Clyra Medical Technologies
• Self financed from outside investment and expected to continue
• FDA 510(k) pre-market clearance received
• Formed a “Medical Advisory Board” of more than 30 physicians,
surgeons and key opinion leaders
• Preparing for clinical work to support extremely high-value uses
• Discussions with strategic partners underway
Recent Highlights from Quarterly Report

11. 11
BioLargo Water
• Poultry farm pre-commercial field pilot was
successful and bid in preparation for full-
scale commercial solution
• Stormwater treatment AOS pilot was officially
launched at facility in Southern California with
grant support
• Spiral reactor validated for scale-up
Recent Highlights from Quarterly Report

12. Target addressable markets
Clean Air Solutions - $1.8B
Landfills: $230M
Transfer stations: $350M
WWT Plants: $720M
Grow Operations: $500M+
H2S *TBD
Wound Care Solutions
$1B
Dental: $264M
Wound care: $75M
Orthopedic: $667M
Plastic Surgery *TBD
Engineering Services
>$100M
Early regional market: $1.5M
Internal + external services & PFAS *TBD
Deliver Clean Water
$8.95B
Beach head market: $246M
12

13. BioLargo Engineering
Trusted industry veterans
Innovators
Solutions Providers
13

14. BioLargo Engineering’s
AEC PFAS Treatment
Technology
• PFAS = “contaminant of the decade”.
Persistent and cumulative
• Linked to adverse health effects
• Orange County est. $850 million to treat 90 wells
already confirmed to be above limits
• Estimated to affect 110 million Americans
• Detection limit disclosure sets the bar on
treatment technologies
• PFAS treatment technology. Scale-up in
progress, proof-of-claim of efficacy achieved.
• Patents pending
• Low energy. High performance. Scalable 14

15. CupriDyne® Clean Industrial Odor
and VOC Eliminator
• Eliminates odors – no
masking
• Non-pesticide, non-toxic
• Saves customers 25-50%
• Top 4 waste handlers under
national contract
15

16. CupriDyne Clean
161616
• Packaged with services:
Engineering, Construction,
Installation, Maintenance &
Service
 Best performance in the
industry
 Safe: Non-toxic & Non-
sensitizing
 Non-pesticide
 Fragrance Optional

17. CupriDyne Clean in action
17

18. U.S. Transfer Stations TAM:
$350 million/year
U.S. Wastewater Treatment TAM:
$720 million/year
Composting: TAM
$120 million/year
CupriDyne Clean in the $1B+ U.S.
Market
Landfills TAM:
$230 million/year

19. Just Getting Started in this Huge Market Opportunity
19
Site Type Potential
sites (US
Market*)
Potential
revenue
per site
per year
1% market
share
3% market
share
10% market
share
TAM (Total
Addressable
Market – US)
Landfills 1,900 $120,000 $2.3M $6.8M $23M $230M
Transfer
Stations
7,600 $48,000 $3.7M $10.9M $37M $350M
Wastewater
Treatment
Plants
(WWT)
15,000 $48,000 $7.2M $21.6M $72M $720M
Totals 24,500 $13.2M $39.3M $132M $1.3B
1Annual revenues are estimated based on our experience with existing customers and estimations that management believes to be reasonable. Revenue per facility may be affected by many factors, including size,
population density, location and weather. Market share calculations are meant to illustrate the opportunity, and are not forecasted revenues
2“Failure to Act, The Economic Impact of Current Investment Trends in Water and Wastewater Treatment Infrastructure” (2011), by American Society of Civil Engineers and Economic Development Research
Group. Figure includes treatment facilities owned and operated by municipalities, as well as those owned and/or operated by private entities contracting with municipalities.
3The top 5 Waste Management companies in the US, as of 2011, operated 624 transfer stations, and 565 landfills. “Municipal Solid Waste Landfills - Economic Impact Analysis for the Proposed New Subpart to the
New Source Performance Standards” (2014), by U.S. Environmental Protection Agency Office of Air and Radiation and Office of Air Quality Planning and Standards. This is a ratio of 1:4 (landfill to transfer stations).
The estimated number of transfer stations is this ratio multiplied by the approximate 1,900 total landfills, and rounded.
4Municipal Solid Waste Landfills - Economic Impact Analysis for the Proposed New Subpart to the New Source Performance Standards” (2014), by U.S. Environmental Protection Agency Office of Air and Radiation
and Office of Air Quality Planning and Standards

20. CupriDyne Clean Pulled Into New Markets
20
Cannabis odor and VOC control
• Distributor partnership with
Cannabusters, subsidiary of Mabre
Corporation
Southeast Asia Wastewater
• MOU signed with BKT, a Korean leader in
wastewater services, and the City of
Daegu

21. 21
Design, Build and Install Expertise

22. 22
Design, Build and Install Expertise

23. 23
Design, Build and Install Expertise

24. 24
Design, Build and Install Expertise

25. 25
Design, Build and Install Expertise

26. 26
Design, Build and Install Expertise

27. AOS
Clean Water Technology
• Low cost
• Lowest power
consumption
27
• Flexible and modular
• Extreme performance

28. AOS – a solution for
Micropollutants
No current feasible solution
AOS negates toxic effects of
micropollutants
Peer-reviewed manuscript in
preparation
28

29. AOS Scalability
• 2 AOS reactor designs
• Modular, scalable technology
• Small physical footprint crucial for certain
applications
• Spiral design – increased scalability
• 5 gallons/min per 8” reactor unit
• 20 units = 144,000 gallons/day
2019-12-12 29

30. First Commercial Pilot in Preparation
30
Demonstration pilot installed at
Sunworks Farm
Full treatment train (pre-
treatment, filtration)
Commercial Pilot proposal
in preparation now at
request of client

33. 33

34. Competition
34
Total OPEX
(CDN$/m3)
Total CAPEX
(CDN $)
Removes
organics
Removes bacteria,
viruses & protozoa
Sensitivity to
turbidity and
TSS
Advanced
Oxidation
System (AOS)
0.17* 83,070* + + +
Ultraviolet (UV) 0.22 172,472 ± - ++
Ozone 0.54 290,447 + - ++
Disinfection performance metrics for bacterial and viral inactivation are assumed to be the same
*Projected values for a Spiral model working at full capacity and low chemical dose

35. •3 demonstration pilots
•Poultry processing
•Stormwater
•WWT* organizing
•Commercial pull
AOS Pilots

36. This document is proprietary and confidential. No part of this document may be disclosed in any
manner to a third party without the prior written consent of Clyra Medical Technologies.
Copyright © 2019 Clyra Medical Technologies Inc.

37. The High Price of Infection and Chronic Wounds
Clyra Medical Technologies Investor Presentation 37
Complications of Infection
in Wound or Surgical
Healing
o Patient pain and discomfort
o Extended hospital stays
o Greatly increased cost
o Delayed healing
o Failure to heal
o Amputations or death
Risks of Hospital Acquired
Infections
o 1.7 Million: CDC estimated number of
Hospital Acquired Infections (HAIs)*
o 100,000: Patient deaths/year from
HAIs
o $45 Billion: Est. annual costs of HAIs
*also known as Healthcare Associated Infections or HAIs
https://www.cdc.gov/HAI/pdfs/hai/Scott_CostPaper.pdf
https://patientcarelink.org/improving-patient-care/healthcare-
acquired-infections-hais/
The Painful Cost of Chronic
Wounds
o 8.7 Million: Patients in U.S.
suffering from chronic non-healing
wounds
o $6.2 Billion: Medicare costs of
diabetic foot ulcers and related
infections
o $28 Billion: Estimated total
treatment costs of chronic wounds in
the U.S.
https://www.apwca.org/news/5310449

38. Clyra Medical Technologies:
Game Changing Solutions to Key Medical Problems
Clyra Medical Technologies Investor Presentation 38
Clyra™ Antimicrobial Products
Infection Prevention & Control
SkinDisc™
Advanced Wound Healing
Two product platforms – both available in multiple formats,
enhanced by proprietary and unique delivery systems.

39. Clyra™ Antimicrobial Products
• A game-changing
antimicrobial
• FDA 510(k) approved
• The result of novel,
patent-pending
cuprous/iodine-based
chemistry
Clyra Medical Technologies Investor Presentation 39
Benefits of Clyra Antimicrobial Technology
✔ Extremely High Antimicrobial Efficacy
✔ Bio-compatible / Safe / No Known
Toxicities
✔ Effective Against Biofilm
✔ Sustained Activity: 10 min to 3+ days
✔ No Known Microbial Resistance
✔ Anti-Inflammatory / Anti-Odor
✔ Tissue Friendly / Non-Toxic / Non-Staining
✔ No Rinsing, Mixing or Dilution Required
✔ Broad Range of Delivery Methods
✔ Environmentally Friendly
• Establishing a new standard in infection
Prevention & Control

40. Proven Effective -
40
• FDA 510(K) approved
• In Vivo Antimicrobial: 100% Planktonic Kill
• In Vivo Anti-Biofilm: 2.5 log kill (vs SOC <1.0
log reduction)
• Sustained Activity: >99.99% 4 log kill, 10 Min to
3+ Days
• Host friendly, pH friendly
• GLP large animal and histology studies complete
2.5
0.8
1.1
2.3
0
0.5
1
1.5
2
2.5
3
Clyra * Aquacel Ag * Povidone IodineCHG
AverageLogReduction(cfu)
Biofilm kill rates
Biofilm Study
Pig study with 1.5 cm wounds
Inoculated to create mature biofilm
Biofilm species: Staphylococcus epidermidis, Pseudomonas aeruginosa, Fusobacterium
Treated with test articles (numerous formulas)
Biopsied 24 hours later
CHG tested is
0.12% CHG
S & N Irrisept is
only .05%

41. Clyra Medical Technologies
Advanced wound
care
Plastic Surgery
Orthopedics
Dental
New gold standard
in advanced
wound care
Gentle & Effective
No known
acquired bacterial
resistance
FDA 510(k)
approved for
first product
41

42. Clyra’s SkinDiscTM
Patented, revolutionary stem cell
wound therapy
Acquired in 2018
250+ patient case studies
performed. 100% limb salvage
with no adverse reaction
42

43. SkinDiscTM Case Study 1 – Diabetic Foot Ulcer
43
Day0Week1
Week2ay0Week1
Week2Week4Week1
Week 1 Week 2 Week 4
Week 2 WDay 0 Week 1
Acellular Dermal
TissueSkinDisc Application
Before
Treatment
 Innovative and
powerful
 Successfully treats
wounds where
competing products
fail
 Saves limbs, saves
lives

44. SkinDiscTM Case Study 2 – Chronic Leg
Wound
44
Highlighted area
is where
SkinDiscTM was
applied
87 year-old patient
with chronic leg
wound
Before
SkinDisc
After
SkinDisc

45. Product Launch Timeline
Clyra Medical Technologies Investor Presentation 45

46. BioLargo’s solutions vetted through collaboration

47. 47
Odor-No-More
 Grow 2-4X
 Make Money
BLEST Engineering
 drive profitability from external contracts
 support development and sales efforts for other divisions
 implement full services solutions for strategic targets- PFAS
Clyra Medical Technologies
 finance through direct investment
 secure clinical validations + FDA approvals for indications of
use
 initial full-scale product launch
BioLargo Water
 finance through direct investment
 complete field pilots for specific commercial applications
 drive commercial sales based on industry-specific pilots
 secure partners
Goals for Coming Year

48. Experienced management with
diverse talents
Ken Code,
BioLargo
CSO Steve Harrison,
Clyra President
Randall Moore,
BLEST President
Richard Smith,
PhD, BioLargo
Water President
Shan Yong,
PhD, BD
Consultant
Joe Provenzano,
Odor-No-More
President
Dr. Tanya
Rhodes, Clyra
CTO
Charles
Dargan,
CFO
Dennis Calvert,
President and CEO
Average 20+ years
executive experience
Industry experts
Exceptionally qualified PhDs
and engineers on staff
48

49. Stock
Symbol:
BLGO
Contact:
Dennis Calvert
President & CEO
BioLargo, Inc.
14921 Chestnut St.
Westminster, CA 92683
(888) 400-2863
dc@BioLargo.com
www.BioLargo.com
49